Advertisement

CNS Drugs

, Volume 19, Issue 1, pp 55–61 | Cite as

Intramuscular Interferon-β-1a

In Patients at High Risk of Developing Clinically Definite Multiple Sclerosis
  • M. Asif A. Siddiqui
  • Keri Wellington
Adis Drug Profile

Abstract

▴ Intramuscular interferon-β-1a, a recombinant interferon-β approved in the US for the treatment of relapsing forms of multiple sclerosis (MS), has also been evaluated in the treatment of patients with a first clinical demyelinating episode and brain lesions consistent with MS confirmed by magnetic resonance imaging (MRI).

▴ In a randomised, double-blind trial, patients at high risk of developing clinically definite MS who received intramuscular interferon-β-1a 30μg once weekly had a 44% reduction in the cumulative probability of developing MS, compared with placebo recipients (rate ratio 0.56; p = 0.002), over a 3-year period after a first, MRI-confirmed demyelinating event.

▴ These results were supported by MRI findings that showed significantly smaller increases in the volume of brain lesions and the number of new/enlarging and gadolinium-enhancing lesions in interferon-β-1a recipients than in those receiving placebo.

▴ A nonblind extension of this trial demonstrated that early treatment with interferon-β-1a significantly reduced the probability of developing MS by 35% (p = 0.03), compared with delayed treatment, over a 5-year period.

▴ Intramuscular interferon-β-1a was generally well tolerated; however, influenza-like syndrome was documented in >50% of patients at high risk of developing clinically definite MS who received the drug.

Keywords

Multiple Sclerosis Magnetic Resonance Imaging Scan Optic Neuritis Avonex Definite Multiple Sclerosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359(9313): 1221–31PubMedCrossRefGoogle Scholar
  2. 2.
    National Multiple Sclerosis Society. Multiple sclerosis information sourcebook [online]. Available from URL: http://www.nationalmssociety.org/sourcebook.asp [Accessed 2004 May 24]
  3. 3.
    Gasperini C, Pozzilli C, Bastianello S, et al. Effect of steroids on Gd-enhancing lesions before and during recombinant beta interferon 1a treatment in relapsing remitting multiple sclerosis. Neurology 1998 Feb; 50: 403–6PubMedCrossRefGoogle Scholar
  4. 4.
    McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001 Jul; 50(1): 121–7PubMedCrossRefGoogle Scholar
  5. 5.
    The Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis: experience of the optic neuritis treatment trial. Neurology 1997 Nov; 49(5): 1404–13CrossRefGoogle Scholar
  6. 6.
    O’Riordan JI, Thompson AJ, Kingsley DPE, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS: a 10-year follow-up. Brain 1998 Mar; 121 (Pt 3): 495–503PubMedCrossRefGoogle Scholar
  7. 7.
    Flachenecker P, Rieckmann P. Early intervention in multiple sclerosis: better outcomes for patients and society? Drugs 2003; 63(15): 1525–33PubMedCrossRefGoogle Scholar
  8. 8.
    Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996 Mar; 39(3): 285–94PubMedCrossRefGoogle Scholar
  9. 9.
    Holliday SM, Benfield P. Interferon-beta-1a: a review of its pharmacological properties and therapeutic potential in multiple sclerosis. Biodrugs 1997 Oct; 8(4): 317–30PubMedCrossRefGoogle Scholar
  10. 10.
    Biogen Inc. Product information: Avonex® (interferon-β-1a) IM injection 30mg prefilled syringe [online]. Available from URL: http://www.avonex.com [Accessed 2004 December 2]
  11. 11.
    Byrnes AA, McArthur JC, Karp CL. Interferon-β therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin-10 production. Ann Neurol 2002 Feb; 51(2): 165–74PubMedCrossRefGoogle Scholar
  12. 12.
    Rudick RA, Ransohoff RM, Lee JC, et al. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology 1998 May; 50(5): 1294–300PubMedCrossRefGoogle Scholar
  13. 13.
    Kumpfel T, Bergh FT, Pollmacher T, et al. Acute effects of interferon beta-1a on plasma cytokine levels in patients with MS. Neurology 2000 Oct 24; 55(2): 1231–3PubMedCrossRefGoogle Scholar
  14. 14.
    Merkelbach S, Kolmel C, Blaes F, et al. Interferon-beta 1a increases serum ciliary neurotrophic factor in multiple sclerosis. Neurology 2001; 56(Suppl. 3): 294Google Scholar
  15. 15.
    Massaro AR. Are there indicators of remyelination in blood or CSF of multiple sclerosis patients? Mult Scler 1998 Jun; 4(3): 228–31PubMedGoogle Scholar
  16. 16.
    Stankoff B, Aigrot MS, Noel F, et al. Ciliary neurotrophic factor (CNTF) enhances myelin formation: a novel role for CNTF and CNTF-related molecules. J Neurosci 2002 Nov 1; 22(21): 9221–7PubMedGoogle Scholar
  17. 17.
    Pachner AR. Anti-IFNβ antibodies in IFNβ-treated MS patients: summary. Neurology 2003 Nov; 61Suppl. 5: S1–5CrossRefGoogle Scholar
  18. 18.
    Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000 Sep 28; 343(13): 898–904PubMedCrossRefGoogle Scholar
  19. 19.
    Bertolotto A, Malucchi S, Sala A, et al. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 2002 Aug; 73(2): 148–53PubMedCrossRefGoogle Scholar
  20. 20.
    Schering Health Care Limited. Product information: Betaferon® (interferon-β-1b) powder and solvent for solution for injection, 250 mg/ml [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2004 May 25]
  21. 21.
    Alam J, McAllister A, Scaramucci J, et al. Pharmacokinetics and pharmacodynamics of interferon beta-1a (IFNβ-1a) in healthy volunteers after intravenous, subcutaneous or intramuscular administration. Clin Drug Invest 1997; 14(1): 35–43CrossRefGoogle Scholar
  22. 22.
    Alam J, Goelz S, Rioux P, et al. Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta-1a (IFNβ-1a) products administered intramuscularly in healthy male and female volunteers. Pharm Res 1997; 14(4): 546–9PubMedCrossRefGoogle Scholar
  23. 23.
    Khan OA, Dhib-Jalbut SS. Serum interferon-β-1a (Avonex) levels following intramuscular injection in relapsing-remitting MS patients. Neurology 1998 Sep; 51(3): 738–42PubMedCrossRefGoogle Scholar
  24. 24.
    Kinkel RP, Kollman C, Glassman A. et al., for the CHAMPIONS Study Group. Interferon beta-1a (Avonex®) delays the onset of clinically definite MS over 5 years of treatment: results from CHAMPIONS Study [abstract no. S29.006]. Neurology 2004; 62(Suppl. 5): 261–2Google Scholar
  25. 25.
    Beck RW, Chandler DL, Cole SR, et al. Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol 2002 Apr; 51: 481–90PubMedCrossRefGoogle Scholar
  26. 26.
    O’Connor P. The effects of intramuscular interferon beta-1a in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS. Clin Ther 2003; 25(11): 2865–74PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • M. Asif A. Siddiqui
    • 1
  • Keri Wellington
    • 1
  1. 1.Adis International LimitedMairangi BayNew Zeland

Personalised recommendations